Core Viewpoint - Shenzhen Lenk Medical Technology Co., Ltd. has completed a multi-million RMB Series A financing round, led by Bangqin Capital, to enhance its high-pressure contrast injection technology and expand its product offerings and international market presence [2]. Market Size and Structure - The global market for high-pressure contrast injectors is projected to reach approximately $2.08 billion in 2024, with consumables accounting for about $1.6 billion and devices around $480 million, expecting a compound annual growth rate (CAGR) of approximately 10.9% from 2025 to 2030 [3]. - In China, the market for high-pressure contrast injectors reached 2.72 billion RMB in 2017, with consumables making up over 60% of the market share, driven by the rapid growth of enhanced CT and interventional imaging [5]. - As of 2023, the market for high-pressure contrast consumables in China has reached 3.97 billion RMB, reflecting a year-on-year growth of 8.4%, with a significant gap in per capita usage compared to the U.S. [6]. Company Overview - Shenzhen Lenk Medical was established in May 2024, focusing on high-pressure contrast and minimally invasive surgical fields, with over 60 intellectual property rights filed or granted [7]. - The company has developed a comprehensive product matrix for high-pressure contrast injectors, including the Nova UC3000 series, which features patented "precise dual-flow mixing" technology for enhanced clinical applications [10]. Team and Engineering Capability - The core team of Lenk Medical comprises members from Mindray Medical and the Chinese Academy of Sciences, possessing extensive experience in electromechanical systems and imaging-related equipment [11]. - Within less than a year, the company has achieved simultaneous progress in R&D, registration, and market expansion, with its devices already in use across multiple provinces and top-tier hospitals [11]. International Expansion - Lenk Medical's products are now available in over 20 countries and regions, with ongoing efforts to build overseas channels and brand recognition through participation in international medical exhibitions [12]. Conclusion - The high-pressure contrast system, while a niche segment within imaging equipment, presents long-term value potential for domestic alternatives due to its technical barriers and clinical integration [13]. The recent financing will support Lenk Medical's continued development in high-pressure contrast technology and its global expansion efforts [13].

报名：首届全球眼科大会 | 议程更新 那么，本次 医学影像展区 都将展出哪些创新产品呢？一起来看看吧！ # GE医疗 展位 ：3R13 展品 ： "英雄"磁共振结合"Sonic深度学习平台" GE医疗 是一家全球领先的医疗科技、诊断药物和数字化解决方案的创新企业，致力于通过整合解决方案和服 务提升医疗效率和精准度。公司业务遍及 160多个国家和地区 ，年营收超196亿美元，拥有全球员工51,000 名。 GE医疗的 SIGNA Hero磁共振设备通过搭载人工智能深度学习Sonic平台 ，实现了"脑心同治"理念的落地。该 设备将传统超过一小时的检查时间缩短至半小时，仅需一次造影剂注射即可完成脑心联合评估，大幅提升检查 效率和成功率。此外，SIGNA Hero还具备 高分辨斑块成像功能 ，能够评估缺血性脑卒中和心脏病风险，为不 明原因卒中患者提供全面诊断信息。 基于SIGNA Hero的脑心同治及肿瘤精准诊疗应用方案已入选《2024年高端医疗装备推广应用项目》，并由天 津医科大学总医院牵头，联合多家医院进行临床应用研究。 # 飞利浦医疗 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 ...